Cryptogenic stroke in patients with patent foramen ovale

Current Atherosclerosis Reports

Volumn 9, Issue 4, 2007, Pages 319-325

  Saver, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

AGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ECHOCARDIOGRAPHY; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; DRUG EFFICACY; ENDOCARDITIS; EQUIPMENT DESIGN; HEART ANEURYSM; HEART ATRIUM FIBRILLATION; HEART ATRIUM SEPTUM DEFECT; HEART SURGERY; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; MAGNETIC RESONANCE ANGIOGRAPHY; MIGRAINE; MONOTHERAPY; PARADOXICAL EMBOLISM; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERICARDITIS; PHLEBOGRAPHY; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; THERAPY EFFECT; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TRANSTHORACIC ECHOCARDIOGRAPHY; VENOUS THROMBOEMBOLISM;

EMBOLISM, PARADOXICAL; FORAMEN OVALE, PATENT; HUMANS; RISK ASSESSMENT; STROKE;

EID: 36048967593     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-007-0039-y     Document Type: Review

References (33)

1. Saver JL: Emerging risk factors for stroke: patent foramen ovale, aortic arch atherosclerosis, antiphospholipid antibodies, and activated protein C resistance. J Stroke Cerebrovasc Dis 1997, 6:167-172.
2. Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984, 59:17-20.
3. Nicholls SC, O'Brian JK, Sutton MG: Venous thromboembolism: detection by duplex scanning. J Vasc Surg 1996, 23:511-516.
4. Meister SG, Grossman W, Dexter L, Dalen JE: Paradoxical embolism. Diagnosis during life. Am J Med 1972, 53:292-8.
5. Stollberger C, Slany J, Schuster I, et al.: The prevalence of deep venous thrombosis in patients with suspected paradoxical embolism. Ann Intern Med 1993, 119:461-465.
6. Kim D, Saver JL: Patent foramen ovale and stroke: what we do and don't know. Rev Neurol Dis 2005, 2:1-7.
7. Cramer SC, Rordorf G, Maki JH, et al.: Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study. Stroke 2004, 35:46-50.
8. Overell JR, Bone I, Lees KR: Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000, 55:1172-1179.
9. Meissner I, Khandheria BK, Heir JA, et al.: Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol 2006, 47:440-445.
10. Di Tullio MR, Sacco RL, Sciacca RR, et al.: Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol 2007, 49:797-802.
11. Cabanes L, Mas JL, Cohen A, et al.: Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993, 24:1865-1873.
12. De Castro S, Cartoni D, Fiorelli M, et al.: Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke 2000, 31:2407-2413.
13. Giardini A, Donti A, Formigari R, et al.: Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. Am J Cardiol 2004, 94:1012-1016.
14. Kartrunen V, Hiltunen L, Rasi V, et al.: Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis 2003, 14:261-268.
15. Becker K, Skalabrin E, Hallam D, Gill E: Ischemic stroke during sexual intercourse: a report of 4 cases in persons with patent foramen ovale. Arch Neurol 2004, 61:1114-1116.
16. Warnmes-van der Heijden EA, Tijssen CC, Egberts AC: Right-to-left shunt and migraine: the strength of the relationship. Cephalalgia 2006, 26:208-213.
17. Azarbal B, Tobis J, Suh W, et al.: Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J Am Coll Cardiol 2005, 45:489-492.
18. Mas JL, Arquizan C, Lamy C, et al.: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001, 345:1740-1746.
19. Homma S, Sacco RL, Di Tullio MR, et al.: Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovalc in Cryptogenic Stroke Study. Circulation 2002, 105:2625-2631.
20. Gasiavelis N, Grinnerno KH, Lindblom D, Dellgren G: Surgical closure of patent foramen ovale in patients with suspected paradoxical embolism: long-term results. Scand Cardiovasc J 2004, 38:375-379.
21. Klotz S, Tjan TD, Berendes E, et al.: Surgical closure of combined symptomatic patent foramen ovale and atrial septum aneurysm for prevention of recurrent cerebral emboli. J Card Surg 2005, 20:370-374.
22. Schneider B, Bauer R: Is surgical closure of patent foramen ovale the gold standard for treating interatrial shunts? An echocardiographic follow-up study. J Am Soc Ecbocardiogr 2005, 18:1385-1391.
23. Tsilimingas NB, Reiter B, Kodolitsch YV, et al.: Surgical revision of an uncommonly dislocated self-expanding Amplatzer septal occluder device. Ann Thorac Surg 2004, 78:686-687.
24. Goldstein JA, Beardslee MA, Xu H, et al.: Infective endocarditis resulting from CardioSEAL closure of a patent foramen ovale. Catheter Cardiovasc Interv 2002, 55:217-220, discussion 221.
25. Wertman B, Azarbal B, Riedl M, Tobis J: Adverse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure. J Am Coll Cardiol 2006, 47:1226-1227.
26. Anzai H, Child J, Natterson B, et al.: Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004, 93:426-431.
27. Krumsdorf U, Ostermayer S, Billinger K, et al.: Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004, 43:302-309.
28. Wohrle J: Closure of patent foramen ovale after cryptogenic stroke. Lancet 2006, 368:350-352.
29. Wahl A, Krumsdorf U, Meier B, et al.: Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. J Am Coll Cardiol 2005, 45:377-380.
30. Windecker S, Wahl A, Nedeltchev K, et al.: Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol 2004, 44:750-758.
31. Off-label practices plague circulatory system device randomized trials. Gray Sheet 2004, 30:18-19.
32. Messe SR, Silverman IE, Kizer JR, et al.: Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004, 62:1042-1050.
33. Sacco RL, Adams R, Albers G, et al.: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37:577-617.